Homologous recombination repair gene mutations predict the efficacy of immune checkpoint inhibitors therapy in colorectal cancer

被引：0
|
作者：
Lin, Y. [1 ]
Zhang, J. [1 ]
Liao, X. [1 ]
Zhang, Y. [1 ]
Luo, M. [1 ]
Li, Q. [1 ]
Xie, M. [1 ]
Liang, C. [1 ]
Liao, S. [1 ]
Zheng, Y. [2 ]
Hu, X. [2 ]
Huang, M. [2 ]
Liang, R. [1 ]
Li, Y. [1 ]
机构：
[1] Guangxi Med Univ, Canc Hosp, Digest Oncol, Nanning, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.970
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
449P
引用
收藏
页码：S558 / S558
页数：1
相关论文
共 50 条
  • [1] Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors
    Lin, Yan
    Luo, Shanshan
    Luo, Min
    Lu, Xuerou
    Li, Qian
    Xie, Mingzhi
    Huang, Yu
    Liao, Xiaoli
    Zhang, Yumei
    Li, Yongqiang
    Liang, Rong
    MOLECULAR CARCINOGENESIS, 2023, 62 (09) : 1271 - 1283
  • [2] DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
    Song, Yipeng
    Huang, Jian
    Liang, Dandan
    Hu, Ying
    Mao, Beibei
    Li, Qiujing
    Sun, Huaibo
    Yang, Ying
    Zhang, Jiao
    Zhang, Henghui
    Chen, Huan
    Liu, Hao
    Zhang, Shukun
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [3] Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
    Lin, Anqi
    Yao, Jiarong
    Cheng, Quan
    Liu, Zaoqu
    Luo, Peng
    Zhang, Jian
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 1693 - 1709
  • [4] Homologous recombination repair gene mutations for DNA repair and immune oncology drug combinations
    Dry, Jonathan R.
    Lai, Zhongwu
    Dougherty, Brian
    Barrett, Carl
    Criscione, Steven
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy
    Silva, Saulo Brito
    Wanderley, Carlos Wagner S.
    Colli, Leandro Machado
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience
    Miao, Ruoyu
    Blue, Kirsten
    Sommerer, Katelyn
    Shah, Anand
    Bottiglieri, Sal
    del Cueto, Alex
    Berry, Darcy K.
    Ho, Teresa T.
    Hicks, James Kevin
    Kim, Dae Won
    CANCERS, 2024, 16 (20)
  • [7] Homologous recombination repair gene mutations in Malaysian prostate cancer patients
    Saeidi, Hamidreza
    Raju, Chandramathi Samudi
    Ismail, Patimah
    Raub, Sayyidi Hamzi Abdul
    Omar, Noorjehan
    Bakrin, Ikmal Hisyam
    CELLULAR AND MOLECULAR BIOLOGY, 2022, 68 (08) : 22 - 26
  • [8] PARP inhibitors in pancreatic cancer with homologous recombination repair gene mutations: A single-institution experience
    Miao, R.
    Yu, J.
    Blue, K.
    Sommerer, K.
    Shah, A.
    Bottiglieri, S.
    Ho, T.
    Hicks, K.
    Kim, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S146 - S146
  • [9] Deciphering the role of homologous recombination deficiency mutations in the response to combined immune checkpoint and PARP inhibitors
    Chaudhuri, Sibapriya
    Thomas, Scott
    Timmerman, Luika
    Munster, Pamela
    CANCER RESEARCH, 2024, 84 (03)
  • [10] Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer
    Lin, Anqi
    Zhang, Hongman
    Hu, Xigang
    Chen, Xiaoting
    Wu, Gang
    Luo, Peng
    Zhang, Jian
    PHARMACOLOGICAL RESEARCH, 2020, 159
12345